. Author manuscript; available in PMC: 2014 Mar 9.

Published in final edited form as: Nat Rev Microbiol. 2008 Jul;6(7):529–540. doi: 10.1038/nrmicro1927

Table 1.

Oncolytic viruses in, or approaching, clinical trials

Virus (strain and modifications)	Tumour target (clinical phase and application)
Adenovirus 5 (dl1520 derivative)	Squamous cell carcinoma of head and neck (approved drug in China; intratumoural)
Adenovirus 5 (PSE-E1A and E3 deleted)	Prostate (I; prostatic)
Herpes simplex virus 1 (ICP34.5 defective)	Glioblastoma multiforme (II; intratumoural)
Vaccinia virus (thymidine kinase knockout and expressing granulocyte–macrophage colony-stimulating factor)	Advanced liver tumours (I–II; intratumoural)
Reovirus (reolysin)	Superficial tumours (I; intralesional)
Newcastle disease virus (PV701)	Bladder, squamous cell carcinoma of head and neck and ovarian (I–II; intravenous)
Measles virus (V protein knockout and expressing the reporter carcinoembryonic antigen or the effector sodium iodide symporter)	Ovarian (I; intratumoural), glioma (I–II; intratumoural) and myeloma (I; intravenous)